Introduction
Bipolar affective disorder (BPAD) is a common psychiatric disorder affecting around 1% of the population. 1 Due to the chronicity and disabling nature of the disease accompanied by a high suicide risk and often severe social implications, BPAD constitutes a major health problem for the affected individuals, their families, and society.
Family, twin, and adoption studies have provided strong evidence for a genetic component in the etiology of BPAD. 2 However, the mode of inheritance is not clear, and a complex genetic basis with several genes simultaneously influencing disease susceptibility may very well be the case. A possible way to detect genetic factors on such complex backgrounds is by association Correspondence: AD Børglum, MD, PhD, Institute of Human Genetics, The Bartholin Building, Aarhus University, DK-8000 Aarhus C, Denmark. E-mail: andersȰhumgen.au.dk Received 16 February 1999; revised and accepted 25 March 1999 studies of candidate genes. 3 An approach like this, using case-control designs, has proved to be useful in the analysis of other complex diseases (eg Alzheimer disease 4 and autoimmune disorders 5 ) , and recent association studies of BPAD have presented evidence suggesting the implication of a number of minor effect susceptibility genes. [6] [7] [8] [9] [10] [11] DOPA decarboxylase (DDC), also known as aromatic l-amino acid decarboxylase (AADC), is a very interesting candidate gene for predisposition to BPAD. Several lines of evidence implicate the catecholamine as well as the indolamine pathway in affective disorders 1, [12] [13] [14] [15] and DDC is involved in both pathways. The enzyme catalyzes the synthesis of two important neurotransmitters, dopamine and serotonin, by decarboxylation of l-dihydroxyphenylalanine (l-DOPA) and l-5-hydroxytryptophan (l-5HTP), respectively. 16 Further downstream in the catecholamine pathway, dopamine is converted to norepinephrine and epinephrine which also function as neurotransmitters. In addition, DDC is thought to be the sole enzyme respon-sible for the synthesis of the trace amines 2-phenylethylamine, p-tyramine, and tryptamine; 17, 18 compounds which have been suggested to act as endogeneous modulators of central neurotransmisson. [19] [20] [21] The DDC gene is located at chromosome 7p11-p13 [22] [23] [24] and consists of 15 exons spanning more than 85 kb. 23 Two promoter regions have been identified: one regulating gene expression in neuronal tissue, the other in non-neuronal tissue. 23, [25] [26] [27] [28] Furthermore, the neuronal and non-neuronal transcripts differ with respect to their first exon, both of which are untranslated.
Although DDC is not a rate-limiting enzyme, it is now clear that it is indeed regulated (for review see 29 ). This fact raises some even more intriguing perspectives as to its potential pathophysiological role, especially concerning a range of neuropsychiatric disorders. In order to examine the involvement of DDC in BPAD we screened a number of individuals for variations in the DDC gene, and subsequently performed an association study of the identified variants in a sample of 192 BPAD patients from Denmark and England, and 572 ethnically matched controls. Following up on the results of this study, an additional sample of 63 English patients with unipolar affective disorder was investigated.
Materials and methods

Case ascertainment and diagnosis
Eighty Danish and 112 English bipolar patients in addition to 63 English patients with recurrent unipolar disorder were included in the study. Ethnically matched controls comprised 223 Danish and 349 English individuals. Informed consent was obtained from all individuals prior to inclusion. Denmark Eighty unrelated Danish Caucasian patients were recruited from in-and outpatient clinics at the Psychiatric Hospital in Aarhus. They were selected among consecutive admissions from a well-defined catchment area of 410 000 individuals and had been admitted an average of four times (range 1-17 times). The cases were all interviewed by TGB using the semistructured interview 'Schedules for Clinical Assessment in Neuropsychiatry' (SCAN version 2.1). 30 Further information was obtained from all available case records. Seventy-nine cases met diagnostic criteria for BPAD according to ICD-10, Diagnostic criteria for research (DCR). 31 One case did not meet DCR for BPAD due to auditory hallucinations in the third person lasting a few minutes and transitory experiences of probable delusional perception, but the case did meet ICD-10 clinical descriptions and diagnostic guidelines for BPAD with mood-incongruent psychotic symptoms 32 and diagnostic criteria for bipolar I disorder according to DSM-IV. 33 All parents and grandparents were of Danish Caucasian descent except two healthy parents who, however, were of Northern European origin. At the interview with the proband, the presence of major psychiatric disorders in relatives was assessed similar to the family history approach. 34 In one-third of the cases, it was possible to directly interview one or both parents concerning the presence of psychiatric illness in the family. Hospital records on parents were obtained whenever possible. Consensus best-estimate of lifetime diagnosis 35 according to ICD-10 DCR was made in collaboration with two independent, senior psychiatrists on the basis of a case narrative, using all available data. In order to allow for polydiagnostic assessment, the Operational Criteria Checklist (OPCRIT) was filled in. 36 The following individuals were excluded: probands with a family history with evidence of bilineal transmission of BPAD; patients who had BPAD secondarily to a somatic disorder or use of alcohol or other psychoactive substances, schizoaffective disorder, mental retardation, or other organic mental disorder; patients with relatives in the blood line known to be diagnosed as having schizophrenia, schizoaffective disorder, or any type of psychosis other than bipolar or unipolar affective disorder. In order to obtain a more homogenous patient sample, in addition to selecting cases based on severity of phenotype, geographic area and ethnicity, only patients with an age of onset before 35 years were included. The controls were ethnically matched Danish Caucasians. They were not interviewed or screened to exclude subjects with a history of psychiatric illness. The study was approved by The Central Scientific Ethical Committee of Denmark and The Danish Data Protection Agency.
England Subjects with bipolar I disorder (n = 93), bipolar II (n = 19) and recurrent major depressive disorder (n = 63) were given a best-estimate lifetime diagnosis according to DSM-IV criteria, on the basis of all available information which included hospital casenotes and structured interviews (SADS-L, SCAN). Excluded were patients reporting blood relatives with schizophrenia in the previous two generations, and subjects with insufficient information to make a diagnosis or with schizoaffective disorder. The subjects were recruited sequentially over a period of several years from three Lithium therapy clinics at the Department of Chemical Pathology, The Institute of Psychiatry, London, Epsom General Hospital and Northern General Hospital, Sheffield. All subjects were Caucasian of English residence and were unrelated. Unrelated, UK Caucasian volunteer control subjects with no major neurological or mental illness were either collected from a general practice surgery in SE England or consisted of community-dwelling subjects who were recuited from general practices in the UK by investigators of the MRC Trial of Assessment and Management of Elderly People in the Community. All scored higher than 25 points on the mini-mental state examination (MMSE).
cDNA preparation
Total RNA was prepared from EBV-transformed lymphoblastoid cell lines of eight Danish patients and freshly isolated lymphocytes of two Danish controls using TRIzol Reagent (Gibco BRL, Rockville, MD, USA). Subsequent RT-PCR was performed on 1 g total RNA according to the manufacturer's instructions using either Titan One Tube RT-PCR System or a traditional two-step procedure applying Expand Reverse Transcriptase (Boehringer Mannheim, Mannheim, Germany) followed by PCR amplification. The latter procedure made use of nested primers in the PCR amplification and was applied when no fragment was obtained by the Titan system. The primers were constructed in accordance with the hepatic cDNA sequence 22 
PCR of promoter and 5Ј untranslated regions
Genomic DNA was isolated from blood samples according to standard procedures. 37 PCR amplification of the untranslated neuronal exon 1 and 627 bp of the adjacent upstream promoter region was carried out under standard conditions. The primers were constructed on basis of the sequence published by Le Van Thai et al (1993; accession No. L05074): DDCprom-up (pos. 74-92) and DDCprom-low (pos. 767-787).
Direct cycle sequencing
Prior to sequencing, the RT-PCR and genomic PCR products were purified using High Pure PCR Product Purification Kit (Boehringer Mannheim). Cycle sequencing was performed by the dideoxy nucleotide chain termination methodology 38 using Dye Terminator Cycle Sequencing Kit with AmpliTaq DNA polymeraseFS (Perkin Elmer, Norwalk, CT, USA). After a step of ethanol precipitation the resolved products were analyzed on a Perkin Elmer ABI-377 apparatus. Both strands were analyzed.
Assay for detection of variants
The detection assay consisted of a multiplex PCR amplification with radioactive 33 P end-labeled primers 39 followed by polyacrylamide gel electrophoresis. The primers for the 1-bp deletion variant were DDCprom-up (5Ј-GCACCCATCAACCAGAAGT-3Ј) and DDCprom-low1del (5Ј-GCCTATCAGCATCTAAAACAT-3Ј) amplifying products of 118-bp and 117-bp. The primers for the 4-bp deletion variant were DDCpromup4del (5Ј-GCTTCGGGGAGGCAGACAC-3Ј) and DDCprom-low (5Ј-GGATGAGGACAAAGAGC AGTA-3Ј) amplifying products of 143-bp and 139-bp. PCR reactions containing 150 ng genomic DNA, 0.4 M of each of the 1-bp deletion primers, 1.2 M of each of the 4-bp deletion primers, 0.2 mM dNTPs, 1 × Incubation buffer (Boehringer Mannheim) and 0.15 U l −1 Taq DNA polymerase (Boehringer Mannheim) were subjected to 5 min primary denaturation at 94°C followed by 30 cycles of 94°C for 30 s, 56°C for 30 s and 72°C for 1 min and a final extension of 6 min at 72°C. PCR products were heat denatured in 50% formamide for 5 min before separation on a 8% polyacrylamide/8 M urea gel. After vacuum drying the gel was autoradiographed for 5 days.
Statistical analysis
Allele frequencies were compared using the 2 test with Yates' correction. Wilcoxon Rank-sum Test with correction for ties was used to compare genotype distributions. Differences were considered statistically significant at P Յ 0.05. Calculations of linkage disequilibrium were carried out using the EH program. 40
Results
Identification of variants
By direct sequencing of RT-PCR and genomic PCR products we were able to screen for sequence variations in the coding region of the DDC gene as well as in the neuron-specific promoter and 5Ј untranslated regions. Ten Danish individuals (eight BPAD patients and two controls) were analyzed in this way.
No variants were observed in the coding sequence. In the neuron-specific promoter and untranslated exon 1 two variants were identified; a 1-bp and a 4-bp deletion, respectively (Figure 1 ). The 1-bp deletion affects a G at position 100 of the sequence presented by Le Van Thai et al (1993; accession No. L05074), corresponding to nucleotide number g.-601 relative to the transcription start site proposed by the same authors. 25 The deletion alters a possible binding site for a family of zinc finger transcription factors, called the NGFI-A family, in a way that may eliminate the binding capacity 41 (see also Discussion). In exon 1 the 4-bp deletion comprises a GAGA sequence (position 722-725, sequence accession No. L05074) located in the beginning of a (GA) 5 repeat array. The consensus nomenclature for the deletion would be c.-65 ٙ -68delGAGA, referring to the neuronspecific cDNA. 42 In Drosophila it is known that such GA-rich sequences may act as binding sites for the important GAGA transcription factor (GAF), 43 and a recent study has shown that a reduction in repeat length from (GA) 4 to (GA) 2 reduces the relative affinity for GAF. 44 
Association study
In order to efficiently assess the prevalence of the deletions in a large number of individuals, a PCR-based detection assay was developed as described in Materials and methods. An illustration of the easily scored results of this assay is shown in Figure 2 .
We berg equilibrium was detected for both of the variants in patients as in controls (P-values from 0.859 to 0.998). Concerning the 4-bp deletion, no significant association with BPAD was observed. In contrast, when the English and Danish samples were combined, a significant association was found between BPAD and the 1-bp deletion. This was the case both when comparing the allele frequencies ( 2 = 4.37, P = 0.037) and the genotype distributions (Wilcoxon Rank-sum Test with correction for ties, P = 0.021). The odds ratio for the allelic association was 1.48 (95% CI: 1.02-2.15), and the corresponding attributable fraction-that is, the proportion of cases that would not occur if the 1-bp deletion was not present-could be calculated to 4.3%. The allele frequencies of the English and Danish controls were not significantly different ( 2 = 2.26, P = 0.133), nor were the allele frequencies of the bipolar patients from the two countries ( 2 = 0.28, P = 0.594).
To test whether this association would apply also to unipolar affective disorder, a sample of 63 English patients suffering from multiple episodes of major depression was subsequently tested ( Table 1) . As opposed to the bipolar patients, the unipolar patients displayed a somewhat lower frequency of the 1-bp deletion than the controls-though, this was far from Using the EH program, 40 the 1-bp deletion was found to be in strong linkage disequilibrium with the wildtype allele of the 4-bp deletion variant in all subgroups of the material (DЈ values from −0.99 to −1.00). Analyzing the whole sample set DЈ was calculated to be −1.00 (complete linkage disequilibrium) with a high degree of confidence ( 2 = 35.09, P Ͻ 10 −5 ).
Discussion
During the last decade considerable efforts have been made to identify the genetic basis of BPAD and other complex disorders in the field of psychiatric genetics. Linkage studies have provided evidence suggesting a number of possible BPAD loci on different chromosomes. 45 However, results have been inconsistent 46 and final proof still awaits the identification of a disease gene in one of these regions. An alternative approach is the direct analysis of candidate genes which presently is one of the most powerful methods to detect disease genes of minor effect.
We report the identification of two deletions in the DDC gene, and association of one of these with BPAD. When evaluating the statistical significance of such associations, it is important to appreciate the fact that it is highly dependent on the a priori probability that the gene variant may confer disease susceptibility. 47 That is, the stronger the evidence appointing the candidate gene, the less stringent confidence limit may be required. As DDC is a regulated enzyme playing a central role in both the catecholamine and indolamine pathways, it is an obvious candidate gene for affective disorder. We have previously reported a linkage analysis of DDC in two Danish BPAD families, obtaining no evidence for linkage. 48 Likewise, no parametric or nonparametric linkage studies have, to our knowledge, presented any evidence for a BPAD locus on chromosome 7p. However, these observations are by no means contradictory to the hypothesis that DDC may act as a susceptibility gene of minor effect, since it would require a very high number of families to detect such an effect by linkage analysis. 49, 50 More important to consider is the functional significance of the gene variant. The 1-bp promoter deletion changes a putative binding site for the NGFI-A family of immediate-early gene-encoded transcription factors known to be expressed in neuronal tissue. 41, 51 The family includes NGFI-A, NGFI-C, Egr3, and Krox20. The single GCGGGGGCG binding site has frequently been referred to as the consensus binding site for this family of transcription factors, but recent studies have shown that there is greater variability in binding sites than has generally been acknowledged and that a sequence similar to that present in the DDC promoter can indeed bind these transcription factors. 41 When the G is deleted in the promoter the recognition sequence changes to a T at the most critical position (pos. 7) and the binding capacity drops to zero for all members of the NGFI-A family. These observations suggest that the 1-bp deletion may have a functional impact on the expression of DDC. We are currently analyzing this aspect in detail using expression assays.
In spite of strong linkage disequilibrium, it may be noticed that the difference in allele frequencies of the 1-bp deletion between patients and controls was not reflected in similar changes in the wild-type allele of the 4-bp deletion variant (Table 1) . However, this is what should be expected if the 4-bp deletion has no influence on disease susceptibility. The strong linkage disequilibrium observed implies that the haplotype comprising both deletions does probably not exist or is very rare. The relative increase among bipolar patients of the haplotype comprising the 1-bp deletion and the wild-type of the 4-bp deletion variant is at the expense of an equivalent joint reduction of the two other existing haplotypes, ie (a) the wild-type/wildtype and (b) the wild-type of the 1-bp deletion variant/the 4-bp deletion. As the latter haplotype is about 2.5 times rarer than the former, its relative reduction in frequency should be 2.5 times less, assuming no association between the 4-bp deletion and BPAD. On this basis, the expected difference in frequency of the 4-bp deletion between bipolar patients and controls can be calculated to be around only 1% ((13.3% − 9.4%)/(2.5 + 1), Table 1 ). Thus, the observed difference of 2.2% (25.6% − 23.4%, Table 1 ) is actually slightly greater than expected, although not significantly. Consequently, for statistical reasons alone it should be relevant to test both variants, also in future association studies. This argument is also true for polymorphisms in other genes displaying the same kind of linkage disequilibrium, an aspect which is sometimes neglected.
Twin and family studies indicate that there is only a partly overlap of genetic factors predisposing to bipolar and unipolar disorder. [52] [53] [54] [55] In particular, family studies limiting the definition of unipolar to recurrent cases tend to find no or very little familial relationship between the two disorders (for review see 2 ) . In line with these data, the present study suggests that DDC may be selectively involved in the etiology of bipolar and not recurrent unipolar disorder. Although the unipolar study was of a preliminary nature, the 1-bp deletion was actually found to be underrepresented in the patients.
We have performed the study on homogeneous populations and the controls have been carefully matched with respect to their ethnical background. Although these precautions were taken it is not possible to completely rule out any bias arrising from population stratification. However, it should be noticed that the same trend-overrepresentation of the 1-bp deletion in bipolar patients-was observed independently in both the English and the Danish material. In order to obtain confirmatory evidence, this initial association should be replicated, preferably using internal controls.
Furthermore, considering the central role of DDC, the two variants identified should be analyzed in a range of other neuropsychiatric disorders including schizophrenia, panic disorder, infantile autism, and Parkinson's disease. Likewise, we are currently investigating the epistatic interaction of DDC with other genes involved in the same pathways or relevant degradation mechanisms in relation to BPAD as well as other disorders.
In conclusion, this study describes the existence of two relatively frequent and possibly functional deletions in the DDC gene, and presents evidence proposing DDC as a minor susceptibility gene for BPAD. Illumination of the complex genetic background for BPAD may eventually allow a more rational diagnosis and treatment of this and related disorders.
